Αρχική World News Limited Effect of Endocrine Therapy on Distant Metastasis-Free Interval in Patients with...

Limited Effect of Endocrine Therapy on Distant Metastasis-Free Interval in Patients with Stage I Low-Risk Breast Cancer, but Fewer Breast Cancer Events

With 8.7 years median follow-up, a subgroup of patients included in the MINDACT study with stage I oestrogen receptor (ER)-positive, HER2-negative, low-risk breast cancer who received no adjuvant systemic therapy had a good 8-year distant metastasis-free interval (DMFI) rate, although a slightly better outcome and lower rates of locoregional recurrence and contralateral breast cancer were observed in patients who received endocrine therapy. Considering the natural history of ER-positive, HER2-negative breast cancer and the projected long-term survival effects of endocrine therapy, the observed effect of adjuvant endocrine therapy as well the side effects should be discussed with patients even at a very low risk of distant metastasis according to Prof. Emiel J.T. Rutgers of the Netherlands Cancer Institute in Amsterdam, The Netherlands and colleagues who published the findings on 30 November 2021 in the Annals of Oncology.

In the randomised, phase III MINDACT study, treatment allocation and randomisation was based on risk stratification. Standard clinical-pathological characteristics were used to determine clinical risk and the 70-gene signature MammaPrint was used to determine genomic risk. Patients identified as low-risk by both methods, did not receive chemotherapy as per study design. These patients were treated according to local guidelines, with most ER-positive patients receiving endocrine therapy.

However, there is also a group of patients in MINDACT who received no adjuvant systemic therapy. As the Netherlands was the largest recruiter for the MINDACT study, and their national guideline permits the omission of all adjuvant systemic therapies in a subgroup of low-risk patients, the majority of the patients in MINDACT who received no adjuvant systemic therapy came from the Netherlands.

The aim of this analysis was to evaluate the survival of patients with breast cancer who participated in the MINDACT study and did not receive any type of adjuvant systemic therapy and compare their outcomes to those patients with similar characteristics who received endocrine therapy.

The authors wrote in the background that adjuvant systemic therapy reduce mortality, but have associated short- and long-term toxicities. Therefore, careful selection of patients likely to benefit from adjuvant systemic therapy is needed. 

Patients with ER-positive, HER2 negative, lymph node negative tumours ≤2cm who received no adjuvant systemic therapy were matched 1:1 to patients with similar tumour characteristics treated with adjuvant endocrine therapy, using propensity score matching and exact matching on age, genomic risk (70-gene signature) and grade.

In a posthoc analysis, DMFI and overall survival (OS) were assessed by Kaplan-Meier analysis and hazard ratios (HR) by Cox regression. Cumulative incidences of locoregional recurrence and contralateral breast cancer were assessed with competing risk analyses.

At 8 years, DMFI rates were 94.8% (95% confidence interval [CI] 92.7-96.9%) in 509 patients receiving no adjuvant systemic therapy, and 97.3% (95% CI 95.8-98.8%) in 509 matched patients who received only endocrine therapy with absolute difference of 2.5% (HR 0.56; 95% CI 0.30-1.03).

No statistically significant difference was seen in 8-year OS rates, 95.4% (95% CI 93.5-97.4%) in patients receiving no adjuvant systemic therapy, and 95.6% (95% CI 93.8-97.5%) in patients receiving only endocrine therapy with absolute difference of 0.2% (HR 0.86; 95% CI 0.53-1.41).

Cumulative incidence rates of locoregional recurrence and contralateral breast cancer were 4.7% (95% CI 3.0-7.0%) and 4.6% (95% CI 2.9-6.9%) in patients receiving no adjuvant systemic therapy versus 1.4% (95% CI 0.6-2.9%) and 1.5% (95% CI 0.6-3.1%) in patients receiving only endocrine therapy.

The authors concluded that in patients with stage I low-risk breast cancer, the effect of endocrine therapy on DMFI was limited, but overall significantly fewer breast cancer events were observed in patients who received endocrine therapy, after the relatively short follow-up of 8 years. These benefits and side effects of endocrine therapy should be discussed with all patients, even those at a very low risk of distant metastasis.

The authors acknowledged the contribution of the European Organisation for Research and Treatment of Cancer and the Breast International Group.

Reference

Lopes Cardozo JMN, Byng D, Drukker CA, et al. Outcome without any adjuvant systemic treatment in stage I ER+/HER2- breast cancer patients included in the MINDACT trial. Annals of Oncology; Published online 30 November 2021. DOI: https://doi.org/10.1016/j.annonc.2021.11.014

Source

NEWSLETTER

Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like
57ΑκόλουθοιΑκολουθήστε

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...

ΠΑΓΚΟΣΜΙΑ ΗΜΕΡΑ ΚΑΡΚΙΝΟΥ

Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ)

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

2-Year-Boy Is So Excited To See Himself In Disney’s ‘Encanto’

The importance of representation in media has been a growing topic of concern, and companies have responded by adding more diversity to their characters,...

Man Walks Entire Continent To Spread Awareness About Mental Health & Suicide Prevention

Matthew Fennell is walking over 3,000 miles across Australia for an important cause and one that is near and dear to his heart. Last year,...

Boy Battling Cancer Becomes Honorary Police Officer, Sworn In To 45 Agencies

At just ten years old, Devarjaye “DJ” Daniel has already been through more than most people go through in their entire lives. DJ has been...

Paclitaxel and Carboplatin Not Inferior When Compared with Paclitaxel and Ifosfamide for the Treatment of Patients with Uterine Carcinosarcoma

With regard to overall survival (OS), paclitaxel and carboplatin was not inferior and demonstrated improved progression-free survival (PFS) when compared with paclitaxel and ifosfamide...

Cancer in My Community: Improving Access to Palliative Care in Indonesia

Cancer in My Community is a Cancer.Net Blog series that shows the global impact of cancer and how people work to care for those with...

Should CAR T Cells Be Used Earlier in People with Non-Hodgkin Lymphoma?

January 13, 2022, by NCI Staff Several approved CAR T-cell therapies work by binding to the CD19 antigen on cancer cells and killing them. Credit: Adapted...